J7516 Inj, cyclosporine 250mgInjection, cyclosporine, 250 mg
J7516 payment limit: $75.649 per 250 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%.
00574-0866-10 Cyclosporine Injection, Padagis US LLC: 10 billing units per package00078-0109-01 Sandimmune, Novartis Pharmaceuticals Corporation: 10 billing units per package (10 AMPULE in 1 BOX / 5 mL in 1 AMPULE)Status E: excluded from the PFS by regulation.
0 of 1 payer prior-auth lists that name J7516 require prior authorization or set conditions.
J7516 appears in 22 coverage policies from Aetna.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Adalimumab (0655) Anakinra (Kineret), Rinvoq, Otezla and Xeljanz, Clindamycin, Metronidazole, Rifampicin, Sulfasalazine, Leflunomide - | listed, no stance | Jul 13, 2026 | payer document |
| Aetna | Anifrolumab-fnia (Saphnelo) (0997) | listed, no stance | Jun 5, 2026 | payer document |
| Aetna | Belimumab (Benlysta) (0818) | listed, no stance | Jun 10, 2026 | payer document |
| Aetna | Eculizumab (0807) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Emapalumab-lzsg (Gamifant) (0948) | listed, no stance | Dec 8, 2025 | payer document |
| Aetna | Extracorporeal Immunoadsorption (Prosorba Column) (0355) | listed, no stance | May 26, 2026 | payer document |
| Aetna | Golimumab (Simponi and Simponi Aria) (0790) | listed, no stance | Jul 31, 2026 | payer document |
| Aetna | Guselkumab (Tremfya) (1011) | listed, no stance | Jun 29, 2026 | payer document |
| Aetna | Hypoxic Ischemic Encephalopathy (0812) Topiramate | not covered | Nov 20, 2025 | payer document |
| Aetna | Inebilizumab-cdon (Uplizna) (0975) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Infliximab (0341) | listed, no stance | Oct 5, 2026 | payer document |
| Aetna | Multiple Sclerosis (0264) Serum neurofilament, Osteopontin, Clemastine fumarate, Intravesical vanilloids, cannabis and cannabinoids | not covered (range J7515-J7516) | Sep 10, 2026 | payer document |
| Aetna | Nipocalimab-aahu (Imaavy) (1083) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (0634) | listed, no stance | Sep 25, 2026 | payer document |
| Aetna | Plasmapheresis/Plasma Exchange/Therapeutic Apheresis (0285) | listed, no stance | Apr 16, 2026 | payer document |
| Aetna | Ravulizumab-cwvz (Ultomiris) (0946) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Risankizumab-rzaa (Skyrizi) (1009) | listed, no stance | Jul 1, 2026 | payer document |
| Aetna | Rituximab (0314) | listed, no stance | Sep 15, 2026 | payer document |
| Aetna | Rozanolixizumab-noli (Rystiggo) (1035) | listed, no stance | Aug 11, 2026 | payer document |
| Aetna | Spesolimab-sbzo (Spevigo) (1013) | listed, no stance | Apr 2, 2026 | payer document |
| Aetna | Tildrakizumab-asmn (Ilumya) (1012) | listed, no stance | Jul 1, 2026 | payer document |
| Aetna | Ustekinumab (0912) | listed, no stance | Jul 1, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.